Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Long-Term Investments (2020 - 2021)

Xeris Biopharma Holdings (XERS) has disclosed Long-Term Investments for 2 consecutive years, with $33.5 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Long-Term Investments changed N/A year-over-year to $33.5 million, compared with a TTM value of $33.5 million through Sep 2021, changed N/A, and an annual FY2020 reading of $96.2 million, changed N/A over the prior year.
  • Long-Term Investments was $33.5 million for Q3 2021 at Xeris Biopharma Holdings, down from $96.2 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $96.2 million in Q4 2020 and bottomed at $33.5 million in Q3 2021.